JansenBPetersG.Foreign body associated infection. J Antimicrob Chemother1993;
32:69–75
2.
VinhDCEmbilJM.Device-related infections: a review. J Long Term Eff Med Implants2005;
15:467–88
3.
WagnerCHanschGM.Mechanisms of bacterial colonization of implants and host response. Adv Exp Med Biol2017;
971:15–27
4.
Levack AE, Cyphert EL, Bostrom MP, Hernandez CJ, von Recum HA, Carli AV. Current Options and Emerging Biomaterials for Periprosthetic Joint Infection. Curr Rheumatol Rep 2018;20:33
5.
JakobsenTH, Eickhardt SR, Gheorghe AG, Stenqvist C, Sonderholm M, Stavnsberg C, Jensen PO, Odgaard A, Whiteley M, Moser C, Hvolris J, Hougen HP, Bjarnsholt T.
Implants induce a new niche for microbiomes. APMIS2018;
126:685–92
6.
Ohrt-NissenS, Fritz BG, Walbom J, Kragh KN, Bjarnsholt T, Dahl B, Manniche C.
Bacterial biofilms: a possible mechanism for chronic infection in patients with lumbar disc herniation – a prospective proof-of-concept study using fluorescence in situ hybridization. APMIS:2018;
126:440–7
7.
BjarnsholtT, Buhlin K, Dufrene YF, Gomelsky M, Moroni A, Ramstedt M, Rumbaugh KP, Schulte T, Sun L, Akerlund B, Romling U.
Biofilm formation – what we can learn from recent developments. J Intern Med2018;
284:332–45
8.
PokrowieckiR.The paradigm shift for drug delivery systems for oral and maxillofacial implants. Drug Delivery2018;
25:1504–15
9.
LackeyJB.Stream enrichment and microbiota. Public Health Rep1956;
71:708–18
10.
LavergneV, Malo M, Gaudelli C, Laprade M, Leduc S, Laflamme P, Rouleau DM.
Clinical impact of positive Propionibacterium acnes cultures in orthopedic surgery. Orthopaed Traumatol Surg Res: OTSR. 2017;
103:307–14
11.
RomanoCLRomanoDMorelliIDragoL.The concept of biofilm-related implant malfunction and “low-grade” infection. Adv Exp Med Biol2017;
971:1–13
12.
Rodriguez-PalaciosA. Institutional Protocols for the Oral Administration (Gavage) of Chemicals and Microscopic Microbial Communities to Mice: Analytical Consensus. 2019; doi:10.1177/1535370219838203
13.
Haley RM, Zuckerman ST, Gormley CA, Korley JN, von Recum HA. Local Delivery Polymer Provides Sustained Anti-fungal Activity of Amphotericin B with Reduced Cytotoxicity. 2019; doi: 10.1177/1535370219837905
14.
HaleyRRecumH. Localized and Targeted Delivery of NSAIDs for Treatment of Inflammation: A Review. 2019; doi: 10.1177/1535370218787770
15.
Zangara MT, McDonald C. How diet and the microbiome shape health or contribute to disease: a mini-review of current models and clinical studies. 2019; doi:10.1177/1535370219826070
16.
Song SJ, Woodhams D, Martino C, Allaband C, Mu A, Javorschi-Miller-Montgomery S, Suchodolski J, Knight R. Engineering the microbiome for animal health and conservation. 2019; doi:10.1177/1535370219830075
17.
DongT, JacobsJ. Nonalcoholic Fatty Liver Disease and the Gut Microbiome: Are Bacteria Responsible for Fatty Liver? 2019; doi:10.1177/1535370219836739
18.
Baim AD, Movahedan A, Farooq AV, Skondra D. The microbiome and ophthalmic disease: a review. 2019; doi:10.1177/1535370218813616
19.
Bryniarski MA, Hamarneh F, Yacoub R. The role of chronic kidney disease associated dysbiosis in cardiovascular disease. 2019; doi:10.1177/1535370219826526
20.
DohlmanAShenX. Mapping the Microbial Interactome: Statistical and Experimental Approaches for Microbiome Network Inference. 2019; doi:10.1177/1535370219836771
21.
ChristoffAP, SereiaAFR, HernandesC, OliveiraLFV Uncovering the hidden microbiota in hospital and built environments: new approaches and solutions. 2019; doi:10.1177/1535370218821857
22.
RenL, HolzknechtR, HolzknechtZ, KotzS, BowlesD, LinSS, McKenney E, ParkerW. Amole-rat’s gut microbiota suggests selective influence of diet on microbial niche space and evolution. 2019; doi:10.1177/1535370219828703
23.
YacoubR, NadkarniGN, McSkimmingDI, ChavesLD, AbyadS, BryniarskiMA, HonanAM, ThomasSA, GowdaM, HeJ, UribarriJ.Fecal microbiota analysis of polycystic kidney disease patients according to renal function, a pilot study. 2019; doi:10.1177/1535370218818175
